<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01313858</url>
  </required_header>
  <id_info>
    <org_study_id>P06554</org_study_id>
    <secondary_id>MK-8259-005</secondary_id>
    <nct_id>NCT01313858</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554)</brief_title>
  <acronym>GO-NICE</acronym>
  <official_title>Non-Interventional Study Investigating the Use of Golimumab (Simponi®) in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to assess the use of golimumab (Simponi®) in participants with rheumatoid
      arthritis, psoriatic arthritis, and ankylosing spondylitis. The study objective is to
      evaluate the clinical safety of golimumab (Simponi®) under real-life, clinical practice
      conditions as assessed by the incidence and type of (serious) adverse events and changes in
      clinical status of participants as assessed by clinical parameters.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Global Impression (CGI) Disease Status</measure>
    <time_frame>Baseline (BL; Month 0), Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24</time_frame>
    <description>The CGI is a non-disease-specific evaluation of participants' overall health status assessed on a 10 mm visual analogue scale (VAS) ranging from &quot;0&quot; (free of complaints) to &quot;10&quot; (strong discomfort). The closer the score to 0, the better the health status.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in FFbH (Funktionsfragebogen Hannover) Questionnaire Score</measure>
    <time_frame>Baseline and Months 3, 6, 9, 12, 15, 18, 21, 24</time_frame>
    <description>The FFbH is a participant questionnaire assessing disability/functional impairment. Ability to perform 18 activities of daily living are scored on a 3 point scale (2=Yes, 1=Yes but with effort, and 0=No or with assistance) and summed. Remaining functional capacity is calculated as the percent of the maximum number of score points (FFbH[%] = (Attained score*100)/(2*n) where n is the number of completed responses) with range from 0 = total loss of functional capacity to 100 = maximal functional capacity. Increase from baseline in FFbH score signifies improvement. The FFbH is similar to Health Assessment Questionnaire (HAQ) but is more widely used in Germany.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score</measure>
    <time_frame>Baseline and Months 3, 6, 12, 18, 24</time_frame>
    <description>The FACIT-F scale assesses self-reported fatigue and its impact upon daily activities and function. 13 items consisting of fatigue, weakness, listlessness, tiredness, trouble with starting things, trouble with finishing things, energy, activity, sleep, eating, help doing activities, frustration, and social activities are scored on a scale of 0 (not at all) to 4 (very much), except energy and activity which are reversed scored. Individual item scores are then summed to provide the final FACIT-F score with range from 0 (lowest) to 52 (highest quality of life). Increase from baseline in FACIT-F score signifies improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in EuroQol- 5 Dimension 3 Level Version (EQ-5D-3L) Questionnaire Score</measure>
    <time_frame>Baseline and Months 6, 12, 18, 24</time_frame>
    <description>The EQ-5D-3L is a health profile questionnaire that assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 1-15 with &quot;1&quot; corresponding to no problems and &quot;15&quot; corresponding to severe problems in the 5 dimensions. Decrease from baseline in EQ-5D-3L signifies improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experienced at Least One Adverse Event</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experienced at Least One Serious Adverse Event</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>A serious adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure that results in death, life-threatening adverse event, permanent or significant disability / unfitness for work, hospital treatment (i.e., admission to hospital) or prolongation of a patient's length of stay, or congenital deformity or birth defect.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">1613</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <condition>Arthritis, Psoriatic</condition>
  <condition>Spondylitis, Ankylosing</condition>
  <arm_group>
    <arm_group_label>Participants with Rheumatoid Arthritis</arm_group_label>
    <description>Simponi®-naïve participants with rheumatoid arthritis given Simponi® 50 mg once a month as a subcutaneous injection. Combination use with methotrexate was recommended.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants with Psoriatic Arthritis</arm_group_label>
    <description>Simponi®-naïve participants with psoriatic arthritis given Simponi® 50 mg once a month as a subcutaneous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants with Ankylosing Spondylitis</arm_group_label>
    <description>Simponi®-naïve participants with ankylosing spondylitis given Simponi® 50 mg once a month as a subcutaneous injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simponi®</intervention_name>
    <arm_group_label>Participants with Rheumatoid Arthritis</arm_group_label>
    <arm_group_label>Participants with Psoriatic Arthritis</arm_group_label>
    <arm_group_label>Participants with Ankylosing Spondylitis</arm_group_label>
    <other_name>Golimumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given concomitantly with Simponi®</description>
    <arm_group_label>Participants with Rheumatoid Arthritis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants in a primary care clinic or office with rheumatoid arthritis, psoriatic
        arthritis, or ankylosing spondylitis for whom the treatment with Simponi® by autoinjector
        device is to be initiated for the first time
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis and treatment
             with Simponi® by autoinjector device is to be initiated for the first time

        Exclusion Criteria:

          -  No specific exclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2011</study_first_submitted>
  <study_first_submitted_qc>March 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2011</study_first_posted>
  <results_first_submitted>September 12, 2016</results_first_submitted>
  <results_first_submitted_qc>September 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 1, 2016</results_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Participants With Rheumatoid Arthritis</title>
          <description>Simponi®-naïve participants with rheumatoid arthritis given Simponi® 50 mg once a month as a subcutaneous injection. Combination use with methotrexate was recommended.</description>
        </group>
        <group group_id="P2">
          <title>Participants With Psoriatic Arthritis</title>
          <description>Simponi®-naïve participants with psoriatic arthritis given Simponi® 50 mg once a month as a subcutaneous injection.</description>
        </group>
        <group group_id="P3">
          <title>Participants With Ankylosing Spondylitis</title>
          <description>Simponi®-naïve participants with ankylosing spondylitis given Simponi® 50 mg once a month as a subcutaneous injection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="524"/>
                <participants group_id="P2" count="546"/>
                <participants group_id="P3" count="543"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="238"/>
                <participants group_id="P2" count="276"/>
                <participants group_id="P3" count="305"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="286"/>
                <participants group_id="P2" count="270"/>
                <participants group_id="P3" count="238"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Premature Treatment Termination</title>
              <participants_list>
                <participants group_id="P1" count="251"/>
                <participants group_id="P2" count="219"/>
                <participants group_id="P3" count="191"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Modified Intention to Treat Population (mITT) population consists of all participants who were treated with Simponi® and have a baseline assessment and at least one additional visit, regardless of any protocol violations during the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Participants With Rheumatoid Arthritis</title>
          <description>Simponi®-naïve participants with rheumatoid arthritis given Simponi® 50 mg once a month as a subcutaneous injection. Combination use with methotrexate was recommended.</description>
        </group>
        <group group_id="B2">
          <title>Participants With Psoriatic Arthritis</title>
          <description>Simponi®-naïve participants with psoriatic arthritis given Simponi® 50 mg once a month as a subcutaneous injection.</description>
        </group>
        <group group_id="B3">
          <title>Participants With Ankylosing Spondylitis</title>
          <description>Simponi®-naïve participants with ankylosing spondylitis given Simponi® 50 mg once a month as a subcutaneous injection.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="474"/>
            <count group_id="B2" value="501"/>
            <count group_id="B3" value="483"/>
            <count group_id="B4" value="1458"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>The mITT population consists of all participants who were treated with Simponi® and have a baseline assessment and at least one additional visit, regardless of any protocol violations during the study.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.9" spread="13.38"/>
                    <measurement group_id="B2" value="50.3" spread="12.07"/>
                    <measurement group_id="B3" value="43.6" spread="12.29"/>
                    <measurement group_id="B4" value="49.6" spread="13.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>The mITT population consists of all participants who were treated with Simponi® and have a baseline assessment and at least one additional visit, regardless of any protocol violations during the study.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="345"/>
                    <measurement group_id="B2" value="271"/>
                    <measurement group_id="B3" value="162"/>
                    <measurement group_id="B4" value="778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="230"/>
                    <measurement group_id="B3" value="321"/>
                    <measurement group_id="B4" value="680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Global Impression (CGI) Disease Status</title>
        <description>The CGI is a non-disease-specific evaluation of participants' overall health status assessed on a 10 mm visual analogue scale (VAS) ranging from &quot;0&quot; (free of complaints) to &quot;10&quot; (strong discomfort). The closer the score to 0, the better the health status.</description>
        <time_frame>Baseline (BL; Month 0), Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24</time_frame>
        <population>The mITT population consists of all participants who were treated with Simponi® and have a baseline assessment and at least one additional visit, regardless of any protocol violations during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Rheumatoid Arthritis</title>
            <description>Simponi®-naïve participants with rheumatoid arthritis given Simponi® 50 mg once a month as a subcutaneous injection. Combination use with methotrexate was recommended.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Psoriatic Arthritis</title>
            <description>Simponi®-naïve participants with psoriatic arthritis given Simponi® 50 mg once a month as a subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>Participants With Ankylosing Spondylitis</title>
            <description>Simponi®-naïve participants with ankylosing spondylitis given Simponi® 50 mg once a month as a subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression (CGI) Disease Status</title>
          <description>The CGI is a non-disease-specific evaluation of participants' overall health status assessed on a 10 mm visual analogue scale (VAS) ranging from &quot;0&quot; (free of complaints) to &quot;10&quot; (strong discomfort). The closer the score to 0, the better the health status.</description>
          <population>The mITT population consists of all participants who were treated with Simponi® and have a baseline assessment and at least one additional visit, regardless of any protocol violations during the study.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="501"/>
                <count group_id="O3" value="483"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="2.21" lower_limit="3.69" upper_limit="6.74"/>
                    <measurement group_id="O2" value="5.5" spread="2.17" lower_limit="2.77" upper_limit="6.01"/>
                    <measurement group_id="O3" value="5.7" spread="2.19" lower_limit="3.69" upper_limit="6.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="2.27" lower_limit="4.10" upper_limit="7.33"/>
                    <measurement group_id="O2" value="3.2" spread="2.25" lower_limit="2.71" upper_limit="6.08"/>
                    <measurement group_id="O3" value="2.9" spread="2.13" lower_limit="4.10" upper_limit="7.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="2.25" lower_limit="4.13" upper_limit="7.58"/>
                    <measurement group_id="O2" value="2.8" spread="2.19" lower_limit="3.80" upper_limit="7.44"/>
                    <measurement group_id="O3" value="2.5" spread="2.09" lower_limit="4.13" upper_limit="7.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.99" lower_limit="4.50" upper_limit="8.08"/>
                    <measurement group_id="O2" value="2.6" spread="2.07" lower_limit="4.97" upper_limit="8.77"/>
                    <measurement group_id="O3" value="2.4" spread="1.87" lower_limit="4.50" upper_limit="8.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="2.11" lower_limit="6.21" upper_limit="9.82"/>
                    <measurement group_id="O2" value="2.4" spread="2.01" lower_limit="3.98" upper_limit="7.89"/>
                    <measurement group_id="O3" value="2.3" spread="1.94" lower_limit="6.21" upper_limit="9.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="1.89"/>
                    <measurement group_id="O2" value="2.3" spread="1.96"/>
                    <measurement group_id="O3" value="2.2" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.97"/>
                    <measurement group_id="O2" value="2.2" spread="1.86"/>
                    <measurement group_id="O3" value="2.2" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="1.99"/>
                    <measurement group_id="O2" value="2.1" spread="1.84"/>
                    <measurement group_id="O3" value="2.2" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.84"/>
                    <measurement group_id="O2" value="2.1" spread="1.95"/>
                    <measurement group_id="O3" value="2.1" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in FFbH (Funktionsfragebogen Hannover) Questionnaire Score</title>
        <description>The FFbH is a participant questionnaire assessing disability/functional impairment. Ability to perform 18 activities of daily living are scored on a 3 point scale (2=Yes, 1=Yes but with effort, and 0=No or with assistance) and summed. Remaining functional capacity is calculated as the percent of the maximum number of score points (FFbH[%] = (Attained score*100)/(2*n) where n is the number of completed responses) with range from 0 = total loss of functional capacity to 100 = maximal functional capacity. Increase from baseline in FFbH score signifies improvement. The FFbH is similar to Health Assessment Questionnaire (HAQ) but is more widely used in Germany.</description>
        <time_frame>Baseline and Months 3, 6, 9, 12, 15, 18, 21, 24</time_frame>
        <population>The mITT population consists of all participants who were treated with Simponi® and have a baseline assessment and at least one additional visit, regardless of any protocol violations during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Rheumatoid Arthritis</title>
            <description>Simponi®-naïve participants with rheumatoid arthritis given Simponi® 50 mg once a month as a subcutaneous injection. Combination use with methotrexate was recommended.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Psoriatic Arthritis</title>
            <description>Simponi®-naïve participants with psoriatic arthritis given Simponi® 50 mg once a month as a subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>Participants With Ankylosing Spondylitis</title>
            <description>Simponi®-naïve participants with ankylosing spondylitis given Simponi® 50 mg once a month as a subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FFbH (Funktionsfragebogen Hannover) Questionnaire Score</title>
          <description>The FFbH is a participant questionnaire assessing disability/functional impairment. Ability to perform 18 activities of daily living are scored on a 3 point scale (2=Yes, 1=Yes but with effort, and 0=No or with assistance) and summed. Remaining functional capacity is calculated as the percent of the maximum number of score points (FFbH[%] = (Attained score*100)/(2*n) where n is the number of completed responses) with range from 0 = total loss of functional capacity to 100 = maximal functional capacity. Increase from baseline in FFbH score signifies improvement. The FFbH is similar to Health Assessment Questionnaire (HAQ) but is more widely used in Germany.</description>
          <population>The mITT population consists of all participants who were treated with Simponi® and have a baseline assessment and at least one additional visit, regardless of any protocol violations during the study.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="501"/>
                <count group_id="O3" value="483"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3 (n=348;361;375)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.29" spread="1.56" lower_limit="2.23" upper_limit="8.34"/>
                    <measurement group_id="O2" value="5.82" spread="1.54"/>
                    <measurement group_id="O3" value="8.66" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=263;310;297)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.71" spread="1.69" lower_limit="2.40" upper_limit="9.30"/>
                    <measurement group_id="O2" value="6.31" spread="1.61"/>
                    <measurement group_id="O3" value="10.01" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=226;265;262)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.78" spread="1.77"/>
                    <measurement group_id="O2" value="7.07" spread="1.69"/>
                    <measurement group_id="O3" value="9.67" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=218;247;247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.70" spread="1.79"/>
                    <measurement group_id="O2" value="7.86" spread="1.73"/>
                    <measurement group_id="O3" value="8.34" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15 (n=188;222;234)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.63" spread="1.89"/>
                    <measurement group_id="O2" value="6.64" spread="1.79"/>
                    <measurement group_id="O3" value="9.04" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (n=168;211;216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.98" spread="1.96"/>
                    <measurement group_id="O2" value="8.99" spread="1.82"/>
                    <measurement group_id="O3" value="8.79" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21 (n=166;198;200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.43" spread="1.97"/>
                    <measurement group_id="O2" value="9.18" spread="1.86"/>
                    <measurement group_id="O3" value="7.95" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=167;198;211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.42" spread="1.97"/>
                    <measurement group_id="O2" value="7.71" spread="1.86"/>
                    <measurement group_id="O3" value="9.51" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FFbH at Month 3 (Month 3 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FFbH at Month 6 (Month 6 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FFbH at Month 9 (Month 9 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FFbH at Month 12 (Month 12 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FFbH at Month 15 (Month 15 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0029</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FFbH at Month 18 (Month 18 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FFbH at Month 21 (Month 21 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0059</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FFbH at Month 24 (Month 24 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FFbH at Month 3 (Month 3 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FFbH at Month 6 (Month 6 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FFbH at Month 9 (Month 9 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FFbH at Month 12 (Month 12 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FFbH at Month 15 (Month 15 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FFbH at Month 18 (Month 18 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FFbH at Month 21 (Month 21 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FFbH at Month 24 (Month 24 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FFbH at Month 3 (Month 3 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FFbH at Month 6 (Month 6 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FFbH at Month 9 (Month 9 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FFbH at Month 12 (Month 12 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FFbH at Month 15 (Month 15 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FFbH at Month 18 (Month 18 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FFbH at Month 21 (Month 21 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FFbH at Month 24 (Month 24 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score</title>
        <description>The FACIT-F scale assesses self-reported fatigue and its impact upon daily activities and function. 13 items consisting of fatigue, weakness, listlessness, tiredness, trouble with starting things, trouble with finishing things, energy, activity, sleep, eating, help doing activities, frustration, and social activities are scored on a scale of 0 (not at all) to 4 (very much), except energy and activity which are reversed scored. Individual item scores are then summed to provide the final FACIT-F score with range from 0 (lowest) to 52 (highest quality of life). Increase from baseline in FACIT-F score signifies improvement.</description>
        <time_frame>Baseline and Months 3, 6, 12, 18, 24</time_frame>
        <population>The mITT population consists of all participants who were treated with Simponi® and have a baseline assessment and at least one additional visit, regardless of any protocol violations during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Rheumatoid Arthritis</title>
            <description>Simponi®-naïve participants with rheumatoid arthritis given Simponi® 50 mg once a month as a subcutaneous injection. Combination use with methotrexate was recommended.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Psoriatic Arthritis</title>
            <description>Simponi®-naïve participants with psoriatic arthritis given Simponi® 50 mg once a month as a subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>Participants With Ankylosing Spondylitis</title>
            <description>Simponi®-naïve participants with ankylosing spondylitis given Simponi® 50 mg once a month as a subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score</title>
          <description>The FACIT-F scale assesses self-reported fatigue and its impact upon daily activities and function. 13 items consisting of fatigue, weakness, listlessness, tiredness, trouble with starting things, trouble with finishing things, energy, activity, sleep, eating, help doing activities, frustration, and social activities are scored on a scale of 0 (not at all) to 4 (very much), except energy and activity which are reversed scored. Individual item scores are then summed to provide the final FACIT-F score with range from 0 (lowest) to 52 (highest quality of life). Increase from baseline in FACIT-F score signifies improvement.</description>
          <population>The mITT population consists of all participants who were treated with Simponi® and have a baseline assessment and at least one additional visit, regardless of any protocol violations during the study.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="501"/>
                <count group_id="O3" value="483"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3 (n=344;356;368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" spread="0.79" lower_limit="3.69" upper_limit="6.74"/>
                    <measurement group_id="O2" value="4.39" spread="0.83" lower_limit="2.77" upper_limit="6.01"/>
                    <measurement group_id="O3" value="5.21" spread="0.78" lower_limit="3.69" upper_limit="6.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=264;311;300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.71" spread="0.85" lower_limit="4.10" upper_limit="7.33"/>
                    <measurement group_id="O2" value="4.40" spread="0.86" lower_limit="2.71" upper_limit="6.08"/>
                    <measurement group_id="O3" value="5.71" spread="0.82" lower_limit="4.10" upper_limit="7.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=215;242;243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.81" spread="0.91" lower_limit="4.13" upper_limit="7.58"/>
                    <measurement group_id="O2" value="5.62" spread="0.93" lower_limit="3.80" upper_limit="7.44"/>
                    <measurement group_id="O3" value="5.86" spread="0.88" lower_limit="4.13" upper_limit="7.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (n=167;212;216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.05" spread="0.99" lower_limit="4.50" upper_limit="8.08"/>
                    <measurement group_id="O2" value="6.87" spread="0.97" lower_limit="4.97" upper_limit="8.77"/>
                    <measurement group_id="O3" value="6.29" spread="0.91" lower_limit="4.50" upper_limit="8.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=162;196;211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.99" spread="1.00" lower_limit="6.21" upper_limit="9.82"/>
                    <measurement group_id="O2" value="5.94" spread="1.00" lower_limit="3.98" upper_limit="7.89"/>
                    <measurement group_id="O3" value="8.01" spread="0.92" lower_limit="6.21" upper_limit="9.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FACIT-F at Month 3 (Month 3 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FACIT-F at Month 6 (Month 6 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FACIT-F at Month 12 (Month 12 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FACIT-F at Month 18 (Month 18 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FACIT-F at Month 24 (Month 24 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FACIT-F at Month 3 (Month 3 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FACIT-F at Month 6 (Month 6 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FACIT-F at Month 12 (Month 12 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FACIT-F at Month 18 (Month 18 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FACIT-F at Month 24 (Month 24 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FACIT-F at Month 3 (Month 3 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FACIT-F at Month 6 (Month 6 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FACIT-F at Month 12 (Month 12 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FACIT-F at Month 18 (Month 18 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in FACIT-F at Month 24 (Month 24 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in EuroQol- 5 Dimension 3 Level Version (EQ-5D-3L) Questionnaire Score</title>
        <description>The EQ-5D-3L is a health profile questionnaire that assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 1-15 with &quot;1&quot; corresponding to no problems and &quot;15&quot; corresponding to severe problems in the 5 dimensions. Decrease from baseline in EQ-5D-3L signifies improvement.</description>
        <time_frame>Baseline and Months 6, 12, 18, 24</time_frame>
        <population>The mITT population consists of all participants who were treated with Simponi® and have a baseline assessment and at least one additional visit, regardless of any protocol violations during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Rheumatoid Arthritis</title>
            <description>Simponi®-naïve participants with rheumatoid arthritis given Simponi® 50 mg once a month as a subcutaneous injection. Combination use with methotrexate was recommended.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Psoriatic Arthritis</title>
            <description>Simponi®-naïve participants with psoriatic arthritis given Simponi® 50 mg once a month as a subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>Participants With Ankylosing Spondylitis</title>
            <description>Simponi®-naïve participants with ankylosing spondylitis given Simponi® 50 mg once a month as a subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EuroQol- 5 Dimension 3 Level Version (EQ-5D-3L) Questionnaire Score</title>
          <description>The EQ-5D-3L is a health profile questionnaire that assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 1-15 with &quot;1&quot; corresponding to no problems and &quot;15&quot; corresponding to severe problems in the 5 dimensions. Decrease from baseline in EQ-5D-3L signifies improvement.</description>
          <population>The mITT population consists of all participants who were treated with Simponi® and have a baseline assessment and at least one additional visit, regardless of any protocol violations during the study.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="501"/>
                <count group_id="O3" value="483"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 (n=254;302;293)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="0.15" lower_limit="3.69" upper_limit="6.74"/>
                    <measurement group_id="O2" value="-1.07" spread="0.14" lower_limit="2.77" upper_limit="6.01"/>
                    <measurement group_id="O3" value="-1.18" spread="0.14" lower_limit="3.69" upper_limit="6.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=211;236;242)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" spread="0.16" lower_limit="4.10" upper_limit="7.33"/>
                    <measurement group_id="O2" value="-1.35" spread="0.15" lower_limit="2.71" upper_limit="6.08"/>
                    <measurement group_id="O3" value="-1.24" spread="0.14" lower_limit="4.10" upper_limit="7.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (n=161;206;211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.11" spread="0.17" lower_limit="4.13" upper_limit="7.58"/>
                    <measurement group_id="O2" value="-1.35" spread="0.16" lower_limit="3.80" upper_limit="7.44"/>
                    <measurement group_id="O3" value="-1.25" spread="0.15" lower_limit="4.13" upper_limit="7.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=162;191;210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" spread="0.17" lower_limit="4.50" upper_limit="8.08"/>
                    <measurement group_id="O2" value="-1.29" spread="0.17" lower_limit="4.97" upper_limit="8.77"/>
                    <measurement group_id="O3" value="-1.51" spread="0.15" lower_limit="4.50" upper_limit="8.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in EQ-5D-3L at Month 6 (Month 6 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in EQ-5D-3L at Month 12 (Month 12 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in EQ-5D-3L at Month 18 (Month 18 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in EQ-5D-3L at Month 24 (Month 24 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in EQ-5D-3L at Month 6 (Month 6 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in EQ-5D-3L at Month 12 (Month 12 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in EQ-5D-3L at Month 18 (Month 18 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in EQ-5D-3L at Month 24 (Month 24 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in EQ-5D-3L at Month 6 (Month 6 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in EQ-5D-3L at Month 12 (Month 12 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in EQ-5D-3L at Month 18 (Month 18 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Least squares mean difference from baseline in EQ-5D-3L at Month 24 (Month 24 minus BL)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced at Least One Adverse Event</title>
        <description>An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.</description>
        <time_frame>Up to 24 months</time_frame>
        <population>The safety population consists of all participants with at least one injection of Simponi®.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Rheumatoid Arthritis</title>
            <description>Simponi®-naïve participants with rheumatoid arthritis given Simponi® 50 mg once a month as a subcutaneous injection. Combination use with methotrexate was recommended.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Psoriatic Arthritis</title>
            <description>Simponi®-naïve participants with psoriatic arthritis given Simponi® 50 mg once a month as a subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>Participants With Ankylosing Spondylitis</title>
            <description>Simponi®-naïve participants with ankylosing spondylitis given Simponi® 50 mg once a month as a subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced at Least One Adverse Event</title>
          <description>An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.</description>
          <population>The safety population consists of all participants with at least one injection of Simponi®.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="524"/>
                <count group_id="O2" value="546"/>
                <count group_id="O3" value="543"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320"/>
                    <measurement group_id="O2" value="309"/>
                    <measurement group_id="O3" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced at Least One Serious Adverse Event</title>
        <description>A serious adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure that results in death, life-threatening adverse event, permanent or significant disability / unfitness for work, hospital treatment (i.e., admission to hospital) or prolongation of a patient's length of stay, or congenital deformity or birth defect.</description>
        <time_frame>Up to 24 months</time_frame>
        <population>The safety population consists of all participants with at least one injection of Simponi®.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Rheumatoid Arthritis</title>
            <description>Simponi®-naïve participants with rheumatoid arthritis given Simponi® 50 mg once a month as a subcutaneous injection. Combination use with methotrexate was recommended.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Psoriatic Arthritis</title>
            <description>Simponi®-naïve participants with psoriatic arthritis given Simponi® 50 mg once a month as a subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>Participants With Ankylosing Spondylitis</title>
            <description>Simponi®-naïve participants with ankylosing spondylitis given Simponi® 50 mg once a month as a subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced at Least One Serious Adverse Event</title>
          <description>A serious adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure that results in death, life-threatening adverse event, permanent or significant disability / unfitness for work, hospital treatment (i.e., admission to hospital) or prolongation of a patient's length of stay, or congenital deformity or birth defect.</description>
          <population>The safety population consists of all participants with at least one injection of Simponi®.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="524"/>
                <count group_id="O2" value="546"/>
                <count group_id="O3" value="543"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 24 months</time_frame>
      <desc>Adverse events are described for the safety population consisting of all participants with at least one injection of Simponi®. Results are reported for the entire study population, not for the individual reporting groups according to underlying disease indication.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>Simponi®-naïve participants with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis given Simponi® 50 mg once a month as a subcutaneous injection.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="204" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>NORMOCHROMIC NORMOCYTIC ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR INSUFFICIENCY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>SINOATRIAL BLOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>TACHYARRHYTHMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE VESTIBULAR SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>EXOSTOSIS OF EXTERNAL EAR CANAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>HYPOACUSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>EXOPHTHALMOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>EYELID OEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>PAROPHTHALMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ADHESIONS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISCOMFORT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL VARICES HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>SUBILEUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>SWOLLEN TONGUE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>CONDITION AGGRAVATED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>DRUG INEFFECTIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>FACIAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>MASS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATIC CYST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ATYPICAL PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>CHLAMYDIAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>ENCEPHALITIC INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>FEBRILE INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>KIDNEY INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>PULMONARY SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>PULMONARY TUBERCULOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>SALPINGO-OOPHORITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>SINOBRONCHITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>CLAVICLE FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>CRANIOCEREBRAL INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>JOINT INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>LIGAMENT RUPTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>LUMBAR VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>PERIPROSTHETIC FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>SKULL FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>SPLENIC RUPTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>COLONOSCOPY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>INVESTIGATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS INADEQUATE CONTROL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ANKYLOSING SPONDYLITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>ARTHROFIBROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>FACET JOINT SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>HAND DEFORMITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>JAW CYST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>JOINT EFFUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>JOINT SWELLING</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>PSORIATIC ARTHROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>SYNOVITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>VERTEBRAL FORAMINAL STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BRAIN NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>CHOLESTEATOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>CHRONIC MYELOID LEUKAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>FIBROMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL STROMAL TUMOUR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>LIP AND/OR ORAL CAVITY CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>MELANOCYTIC NAEVUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>METASTASES TO BONE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>NON-HODGKIN'S LYMPHOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>PROSTATIC ADENOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>SALIVARY GLAND NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>BURNING SENSATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>CARPAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>CEREBELLAR INFARCTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>CUBITAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>DEMYELINATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>FACIAL PARESIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>MONOPARESIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>BURNOUT SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>MAJOR DEPRESSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>NEUROGENIC BLADDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>EPIDIDYMITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>MENORRHAGIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>VAGINAL EROSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ALVEOLITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>BRONCHIECTASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>NIGHT SWEATS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>PUSTULAR PSORIASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>AUTONOMIC GANGLIONECTOMY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>BLADDER OPERATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>BURSA REMOVAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>CARDIAC OPERATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>CHOLECYSTECTOMY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>CHOLESTEATOMA REMOVAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>DRUG THERAPY CHANGED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL ABLATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>FOOT OPERATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>GALLBLADDER OPERATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>HIP ARTHROPLASTY</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>HOSPITALISATION</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>HYSTERECTOMY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>JOINT ARTHROPLASTY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>KNEE ARTHROPLASTY</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>KNEE OPERATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>LAXATIVE SUPPORTIVE CARE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>LIMB OPERATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>POLYPECTOMY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>PROSTHESIS IMPLANTATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>RADIOACTIVE IODINE THERAPY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>SHOULDER ARTHROPLASTY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>SHOULDER OPERATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>SPINAL DECOMPRESSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>SPINAL FUSION SURGERY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>SPINAL OPERATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>SYNOVECTOMY</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>TENDON SHEATH INCISION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>TENOTOMY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>TOE OPERATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>VARICOSE VEIN OPERATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>VASCULAR GRAFT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>WRIST SURGERY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>LYMPHOEDEMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
              <event>
                <sub_title>VENOUS INSUFFICIENCY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="315" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG INEFFECTIVE</sub_title>
                <counts group_id="E1" events="315" subjects_affected="315" subjects_at_risk="1613"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

